<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01567865</url>
  </required_header>
  <id_info>
    <org_study_id>JEV05 (VAC004)</org_study_id>
    <nct_id>NCT01567865</nct_id>
  </id_info>
  <brief_title>Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine</brief_title>
  <official_title>A Clinical Trial in Healthy Infants to Assess Lot-to-lot Consistency of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Non-inferiority With Respect to an Earlier Product.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PATH</source>
  <brief_summary>
    <textblock>
      The proposed study is a four-arm double-blind randomized controlled single center trial to
      evaluate, by examining post-vaccination seroprotection titers, the lot-to-lot consistency of
      three lots of Japanese Encephalitis live attenuated SA 14-14-2 vaccine (LJEVac) manufactured
      in a new good manufacture practice (GMP) facility, and to establish non-inferiority of the
      new vaccine in comparison to a single lot of the same vaccine manufactured in the existing
      facility. The study aimed to enroll a total of 1,000 Bangladeshi infants aged 10 to 12
      months. In addition to providing immunogenicity data, this study provided local safety data
      of JE live attenuated SA 14-14-2 vaccine among Bangladeshi children. This is the first step
      to secure licensure for this life-saving vaccine in Bangladesh as well as provide data to
      support WHO prequalification of JE live attenuated SA 14-14-2 vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number/Percentage of Subjects With Demonstrated Seroprotection</measure>
    <time_frame>28 days post-vaccination</time_frame>
    <description>Seroprotection was defined as a serum antibody titer equal to or greater than 1:10, as measured by Plaque reduction neutralization test (PRNT). The end point for neutralization was the highest dilution of serum reducing the number of plaques by 50%, compared with a negative serum control.
In 2004, a group of experts under the leadership of the WHO recommended that seroprotection (SP) against JEV be defined as a neutralizing anti-JEV antibody serum titer ≥1:10 as determined by PRNT [Hombach et al. 2005]. Accordingly, a titer of ≥1:10 was adopted as an indicator of seroprotection in this study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMT)</measure>
    <time_frame>28 days post-vaccination</time_frame>
    <description>Geometric Mean Titers of Neutralizing anti-JEV antibody</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number/Percentage of Subjects With an Immediate Solicited Local or Systemic Reactogenicity Event (RE)</measure>
    <time_frame>Within 30 minutes of vaccination</time_frame>
    <description>Subjects were monitored for the following adverse events and categorized as events almost certainly related to receipt of the vaccine:
Redness Swelling Tenderness Dyspnea Cyanosis Loose Stools Vomiting Convulsion Fever (37 degrees Celsius or greater, axillary) Hives (urticaria) Angioedema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number/Percentage of Subjects With a Solicited Local or Systemic Reactogenicity Event Within 7 Days After Vaccination</measure>
    <time_frame>Within 7 days of vaccination</time_frame>
    <description>Collected by a home visit to observe the subject and interview his/her parent or guardian occurrence and severity of solicited injection site reactogenicity events (REs) related to vaccination and solicited systemic REs or other AEs that might or might not be related to the prior receipt of vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number/Percentage of Subjects With Other Adverse Events (AE) During the Study</measure>
    <time_frame>Between 7 and 28 days of vaccination</time_frame>
    <description>Adverse events other than solicited reactogenicities were obtained through review of medical history when subject returned to clinic. They were graded for severity and rated by the PI for possible relationship to vaccination throughout the 28 days study period.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">818</enrollment>
  <condition>Japanese Encephalitis</condition>
  <arm_group>
    <arm_group_label>Reference Lot</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lot of Vaccine produced in existing facility</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New Lot #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First lot of vaccine produced in new facility</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New Lot #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second lot of vaccine produced in new facility</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New Lot #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Third lot of vaccine produced in new facility</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccine produced in existing facility</intervention_name>
    <description>Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
    <arm_group_label>Reference Lot</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccine produced in new facility</intervention_name>
    <description>Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
    <arm_group_label>New Lot #1</arm_group_label>
    <arm_group_label>New Lot #2</arm_group_label>
    <arm_group_label>New Lot #3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infant's parent(s) or legal guardian(s) willing to provide signed informed consent.

          -  Healthy infants aged 10 to 12 months at enrolment residing in Matlab Health and
             Demographic Surveillance System (HDSS) intervention area who have completed all doses
             of Expanded Programme on Immunization (EPI) immunizations at least 4 weeks prior to
             enrolment: Bacillus Calmette-Guerin vaccine (BCG), Diphtheria-pertussis-tetanus
             vaccine (DPT), Hepatitis B (HBV), Haemophilus influenzae type (Hib), oral polio
             vaccine (OPV) and measles

        Exclusion Criteria:

          -  Acute medical illness with or without fever within the last 72 hours or an axillary
             temperature (≥ 37.5°C ) at the time of vaccination.

          -  Use of antibiotics or antipyretics within the last 72 hours prior to enrolment.

          -  Severely or moderately malnourished infants (&lt;-3 Z score).

          -  History of prematurity (&lt; 36 weeks of pregnancy).

          -  Underlying medical condition such as failure to thrive, inborn errors of metabolism,
             bronchopulmonary dysplasia, or any major congenital abnormalities requiring surgery or
             chronic treatment.

          -  History of serious chronic disease (e.g., cardiac, renal, neurologic, metabolic,
             rheumatologic, hematologic, or bleeding disorder).

          -  Known or suspected impairment of immunologic function.

          -  History of documented or suspected encephalitis or meningitis.

          -  History of seizures, including history of febrile seizures, or any other neurologic
             disorder.

          -  History of JE infection.

          -  Prior receipt of a JE vaccine.

          -  Received measles vaccine within 4 weeks prior to, or scheduled to receive a
             vaccination during, the conduct of this trial.

          -  Prior or anticipated receipt of immune globulin or other blood products, or injected
             or oral corticosteroids or other immune modulator therapy within 6 weeks of
             administration of the study vaccine.

          -  Serious adverse reactions (e.g. urticaria, angioedema, shock, breathlessness following
             vaccination or any life threatening condition) with any previous EPI vaccine.

          -  Unable to attend the scheduled visits or comply with the study procedures.

          -  Enrolled in another clinical trial involving any therapy.

          -  Any condition that in the opinion of the investigator, would pose a health risk to the
             child, or interfere with the evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Months</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K Zaman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICCDR,B</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICDDR,B</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2012</study_first_posted>
  <results_first_submitted>April 13, 2018</results_first_submitted>
  <results_first_submitted_qc>April 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 13, 2018</results_first_posted>
  <last_update_submitted>November 12, 2018</last_update_submitted>
  <last_update_submitted_qc>November 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis, Japanese</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Reference Lot</title>
          <description>Lot of Vaccine produced in existing facility
Vaccine produced in existing facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
        </group>
        <group group_id="P2">
          <title>New Lot #1</title>
          <description>First lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
        </group>
        <group group_id="P3">
          <title>New Lot #2</title>
          <description>Second lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
        </group>
        <group group_id="P4">
          <title>New Lot #3</title>
          <description>Third lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Enrolled and Vaccinated (Day 0)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="220"/>
                <participants group_id="P3" count="211"/>
                <participants group_id="P4" count="224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="220"/>
                <participants group_id="P3" count="211"/>
                <participants group_id="P4" count="224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Evaluated for Immunogenicity</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="220"/>
                <participants group_id="P3" count="211"/>
                <participants group_id="P4" count="224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="195"/>
                <participants group_id="P3" count="192"/>
                <participants group_id="P4" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sero+ for anti-JEV at Visit 1</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing blood sample</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Per-protocol population</population>
      <group_list>
        <group group_id="B1">
          <title>Reference Lot</title>
          <description>Lot of Vaccine produced in existing facility
Vaccine produced in existing facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
        </group>
        <group group_id="B2">
          <title>New Lot #1</title>
          <description>First lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
        </group>
        <group group_id="B3">
          <title>New Lot #2</title>
          <description>Second lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
        </group>
        <group group_id="B4">
          <title>New Lot #3</title>
          <description>Third lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="146"/>
            <count group_id="B2" value="195"/>
            <count group_id="B3" value="192"/>
            <count group_id="B4" value="194"/>
            <count group_id="B5" value="727"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.8" spread=".68"/>
                    <measurement group_id="B2" value="10.9" spread=".73"/>
                    <measurement group_id="B3" value="10.8" spread=".65"/>
                    <measurement group_id="B4" value="10.9" spread=".7"/>
                    <measurement group_id="B5" value="10.9" spread=".7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="366"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="96"/>
                    <measurement group_id="B5" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bangladesh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="192"/>
                    <measurement group_id="B4" value="194"/>
                    <measurement group_id="B5" value="727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number/Percentage of Subjects With Demonstrated Seroprotection</title>
        <description>Seroprotection was defined as a serum antibody titer equal to or greater than 1:10, as measured by Plaque reduction neutralization test (PRNT). The end point for neutralization was the highest dilution of serum reducing the number of plaques by 50%, compared with a negative serum control.
In 2004, a group of experts under the leadership of the WHO recommended that seroprotection (SP) against JEV be defined as a neutralizing anti-JEV antibody serum titer ≥1:10 as determined by PRNT [Hombach et al. 2005]. Accordingly, a titer of ≥1:10 was adopted as an indicator of seroprotection in this study.</description>
        <time_frame>28 days post-vaccination</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Reference Lot</title>
            <description>Lot of Vaccine produced in existing facility
Vaccine produced in existing facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O2">
            <title>New Lot #1</title>
            <description>First lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O3">
            <title>New Lot #2</title>
            <description>Second lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O4">
            <title>New Lot #3</title>
            <description>Third lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O5">
            <title>All New Lots</title>
            <description>All subjects receiving vaccine from the new facility (Lot 1, 2, or 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects With Demonstrated Seroprotection</title>
          <description>Seroprotection was defined as a serum antibody titer equal to or greater than 1:10, as measured by Plaque reduction neutralization test (PRNT). The end point for neutralization was the highest dilution of serum reducing the number of plaques by 50%, compared with a negative serum control.
In 2004, a group of experts under the leadership of the WHO recommended that seroprotection (SP) against JEV be defined as a neutralizing anti-JEV antibody serum titer ≥1:10 as determined by PRNT [Hombach et al. 2005]. Accordingly, a titer of ≥1:10 was adopted as an indicator of seroprotection in this study.</description>
          <population>Per protocol population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="192"/>
                <count group_id="O4" value="194"/>
                <count group_id="O5" value="581"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Seroprotection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="160"/>
                    <measurement group_id="O3" value="154"/>
                    <measurement group_id="O4" value="164"/>
                    <measurement group_id="O5" value="478"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No seroprotection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses: each new lot does not differ in seroprotection (SP) rates among each other by more than 10%.
Slower than anticipated enrollment resulted in a smaller number of subjects with antibody response data for analysis. Consequently, additional power estimates were made in anticipation of the occurrence of smaller sample sizes. With a total study population of only 772 subjects, the power of the study to test lot-to-lot consistency declined from 90% to 85%.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots of new GMP facility LJEVac would be considered equivalent (i.e., the SP does not differ between lots by ≥10%) if all 3 null hypotheses are rejected, and the alternate hypotheses are accepted.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.97</ci_lower_limit>
            <ci_upper_limit>9.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses: each new lot does not differ in seroprotection (SP) rates among each other by more than 10%.
Slower than anticipated enrollment resulted in a smaller number of subjects with antibody response data for analysis. Consequently, additional power estimates were made in anticipation of the occurrence of smaller sample sizes. With a total study population of only 772 subjects, the power of the study to test lot-to-lot consistency declined from 90% to 85%.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots of new GMP facility LJEVac would be considered equivalent (i.e., the SP does not differ between lots by ≥10%) if all 3 null hypotheses are rejected, and the alternate hypotheses are accepted.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>The 95% CI for the difference in rates is calculated based on the Newcombe-Wilson method without continuity correction.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.92</ci_lower_limit>
            <ci_upper_limit>4.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses: each new lot does not differ in seroprotection (SP) rates among each other by more than 10%.
Slower than anticipated enrollment resulted in a smaller number of subjects with antibody response data for analysis. Consequently, additional power estimates were made in anticipation of the occurrence of smaller sample sizes. With a total study population of only 772 subjects, the power of the study to test lot-to-lot consistency declined from 90% to 85%.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots of new GMP facility LJEVac would be considered equivalent (i.e., the SP does not differ between lots by ≥10%) if all 3 null hypotheses are rejected, and the alternate hypotheses are accepted.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.94</ci_lower_limit>
            <ci_upper_limit>3.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: reference lot vs. Lot 1, 2, and 3 combined do differ in seroprotection (SP) rates among each other by more than 10%.
Slower than anticipated enrollment resulted in a smaller number of subjects with antibody response data for analysis. Consequently, additional power estimates were made in anticipation of the occurrence of smaller sample sizes. The power of the study to test non-inferiority of the combined new lots compared to the reference lot dropped from 99% to 87%.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The new GMP facility lots will be considered non-inferior (i.e., equivalent) to the existing facility lot if the null hypothesis is rejected and the alternate hypothesis is accepted.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>The 95% CI for the difference in rates is calculated based on the Newcombe-Wilson method without continuity correction.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.74</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMT)</title>
        <description>Geometric Mean Titers of Neutralizing anti-JEV antibody</description>
        <time_frame>28 days post-vaccination</time_frame>
        <population>Per-Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Reference Lot</title>
            <description>Lot of Vaccine produced in existing facility
Vaccine produced in existing facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O2">
            <title>New Lot #1</title>
            <description>First lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O3">
            <title>New Lot #2</title>
            <description>Second lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O4">
            <title>New Lot #3</title>
            <description>Third lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O5">
            <title>All New Lots</title>
            <description>All subjects receiving vaccine from the new facility (Lot 1, 2, or 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT)</title>
          <description>Geometric Mean Titers of Neutralizing anti-JEV antibody</description>
          <population>Per-Protocol Population</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="192"/>
                <count group_id="O4" value="194"/>
                <count group_id="O5" value="581"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" lower_limit="59.6" upper_limit="100.4"/>
                    <measurement group_id="O2" value="52.8" lower_limit="42.9" upper_limit="65.1"/>
                    <measurement group_id="O3" value="53.4" lower_limit="42.4" upper_limit="67.2"/>
                    <measurement group_id="O4" value="62.8" lower_limit="50.3" upper_limit="78.4"/>
                    <measurement group_id="O5" value="56.2" lower_limit="49.5" upper_limit="63.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number/Percentage of Subjects With an Immediate Solicited Local or Systemic Reactogenicity Event (RE)</title>
        <description>Subjects were monitored for the following adverse events and categorized as events almost certainly related to receipt of the vaccine:
Redness Swelling Tenderness Dyspnea Cyanosis Loose Stools Vomiting Convulsion Fever (37 degrees Celsius or greater, axillary) Hives (urticaria) Angioedema</description>
        <time_frame>Within 30 minutes of vaccination</time_frame>
        <population>All study subjects receiving vaccine were included in this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Reference Lot</title>
            <description>Lot of Vaccine produced in existing facility
Vaccine produced in existing facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O2">
            <title>New Lot #1</title>
            <description>First lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O3">
            <title>New Lot #2</title>
            <description>Second lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O4">
            <title>New Lot #3</title>
            <description>Third lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects With an Immediate Solicited Local or Systemic Reactogenicity Event (RE)</title>
          <description>Subjects were monitored for the following adverse events and categorized as events almost certainly related to receipt of the vaccine:
Redness Swelling Tenderness Dyspnea Cyanosis Loose Stools Vomiting Convulsion Fever (37 degrees Celsius or greater, axillary) Hives (urticaria) Angioedema</description>
          <population>All study subjects receiving vaccine were included in this measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="211"/>
                <count group_id="O4" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Any immediate RE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No immediate RE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="214"/>
                    <measurement group_id="O3" value="206"/>
                    <measurement group_id="O4" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number/Percentage of Subjects With a Solicited Local or Systemic Reactogenicity Event Within 7 Days After Vaccination</title>
        <description>Collected by a home visit to observe the subject and interview his/her parent or guardian occurrence and severity of solicited injection site reactogenicity events (REs) related to vaccination and solicited systemic REs or other AEs that might or might not be related to the prior receipt of vaccine</description>
        <time_frame>Within 7 days of vaccination</time_frame>
        <population>All subjects receiving the vaccine were assessed for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Reference Lot</title>
            <description>Lot of Vaccine produced in existing facility
Vaccine produced in existing facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O2">
            <title>New Lot #1</title>
            <description>First lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O3">
            <title>New Lot #2</title>
            <description>Second lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O4">
            <title>New Lot #3</title>
            <description>Third lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects With a Solicited Local or Systemic Reactogenicity Event Within 7 Days After Vaccination</title>
          <description>Collected by a home visit to observe the subject and interview his/her parent or guardian occurrence and severity of solicited injection site reactogenicity events (REs) related to vaccination and solicited systemic REs or other AEs that might or might not be related to the prior receipt of vaccine</description>
          <population>All subjects receiving the vaccine were assessed for this measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="211"/>
                <count group_id="O4" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Any RE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No RE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="145"/>
                    <measurement group_id="O3" value="130"/>
                    <measurement group_id="O4" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number/Percentage of Subjects With Other Adverse Events (AE) During the Study</title>
        <description>Adverse events other than solicited reactogenicities were obtained through review of medical history when subject returned to clinic. They were graded for severity and rated by the PI for possible relationship to vaccination throughout the 28 days study period.</description>
        <time_frame>Between 7 and 28 days of vaccination</time_frame>
        <population>All subjects receiving the vaccine were evaluated for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Reference Lot</title>
            <description>Lot of Vaccine produced in existing facility
Vaccine produced in existing facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O2">
            <title>New Lot #1</title>
            <description>First lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O3">
            <title>New Lot #2</title>
            <description>Second lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
          <group group_id="O4">
            <title>New Lot #3</title>
            <description>Third lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
          </group>
        </group_list>
        <measure>
          <title>Number/Percentage of Subjects With Other Adverse Events (AE) During the Study</title>
          <description>Adverse events other than solicited reactogenicities were obtained through review of medical history when subject returned to clinic. They were graded for severity and rated by the PI for possible relationship to vaccination throughout the 28 days study period.</description>
          <population>All subjects receiving the vaccine were evaluated for this measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="211"/>
                <count group_id="O4" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Any AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="119"/>
                    <measurement group_id="O4" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days post-vaccination</time_frame>
      <desc>Adverse events other than solicited reactogenicities within the time frame. If the parent/guardian failed to come on day 28, a maximum of 4 days was allowed for follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>Reference Lot</title>
          <description>Lot of Vaccine produced in existing facility
Vaccine produced in existing facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
        </group>
        <group group_id="E2">
          <title>New Lot #1</title>
          <description>First lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
        </group>
        <group group_id="E3">
          <title>New Lot #2</title>
          <description>Second lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
        </group>
        <group group_id="E4">
          <title>New Lot #3</title>
          <description>Third lot of vaccine produced in new facility
Vaccine produced in new facility: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Acute watery diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Acute gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Severe pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Mucous stools</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Rhinorhhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pruritis generalized</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Lower than anticipated rates of enrollment across all groups made it necessary to analyze antibody response data in smaller samples than initially planned. This adversely influenced the precision of all estimates (i.e., resulted in broader 95% CIs)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jorge Flores</name_or_title>
      <organization>PATH</organization>
      <phone>(202) 822-0033</phone>
      <email>jeflores@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

